ADC for Differentiation between Posttreatment Changes and Recurrence in Head and Neck Cancer: A Systematic Review and Meta-analysis

References

1. 1.↵
   1. Saito N,
   2. Nadgir RN,
   3. Nakahira M, et al

   . Posttreatment CT and MR imaging in head and neck cancer: What the radiologist needs to know. Radiographics 2012;32:1261–82 doi:10.1148/rg.325115160 pmid:22977017

   CrossRefPubMed
2. 2.↵
   1. Hermans R

   . Posttreatment imaging in head and neck cancer. Eur J Radiology 2008;66:501–11 doi:10.1016/j.ejrad.2008.01.021 pmid:18328660

   CrossRefPubMed
3. 3.↵
   1. Baba A,
   2. Ojiri H,
   3. Ikeda K, et al

   . Essentials on oncological imaging: postoperative computed tomography and magnetic resonance imaging of oral tongue cancer. Can Assoc Radiol J 2018;69:458–67 doi:10.1016/j.carj.2018.08.001 pmid:30390963

   CrossRefPubMed
4. 4.↵
   1. Aiken AH,
   2. Rath TJ,
   3. Anzai Y, et al

   . ACR Neck Imaging Reporting and Data Systems (NI-RADS): a white paper of the ACR NI-RADS Committee. J Am Coll Radiol 2018;15:1097–108 doi:10.1016/j.jacr.2018.05.006 pmid:29983244

   CrossRefPubMed
5. 5.↵
   1. Tshering Vogel DW,
   2. Zbaeren P,
   3. Geretschlaeger A, et al

   . Diffusion-weighted MR imaging including bi-exponential fitting for the detection of recurrent or residual tumour after (chemo)radiotherapy for laryngeal and hypopharyngeal cancers. Eur Radiol 2013;23:562–69 doi:10.1007/s00330-012-2596-x pmid:22865270

   CrossRefPubMed
6. 6.↵
   1. Hwang I,
   2. Choi SH,
   3. Kim YJ, et al

   . Differentiation of recurrent tumor and posttreatment changes in head and neck squamous cell carcinoma: application of high b-value diffusion-weighted imaging. AJNR Am J Neuroradiol 2013;34:2343–48 doi:10.3174/ajnr.A3603 pmid:23811978

   Abstract/FREE Full Text
7. 7.↵
   1. Razek AA,
   2. Gaballa G,
   3. Ashamalla G, et al

   . Dynamic susceptibility contrast perfusion-weighted magnetic resonance imaging and diffusion-weighted magnetic resonance imaging in differentiating recurrent head and neck cancer from postradiation changes. J Comput Assist Tomogr 2015;39:849–54 doi:10.1097/RCT.0000000000000311 pmid:26359584

   CrossRefPubMed
8. 8.↵
   1. Abdel Razek AA

   . Arterial spin labelling and diffusion-weighted magnetic resonance imaging in differentiation of recurrent head and neck cancer from post-radiation changes. J Laryngol Otol 2018;132:923–28 doi:10.1017/S0022215118001743 pmid:30387410

   CrossRefPubMed
9. 9.↵
   1. Ailianou A,
   2. Mundada P,
   3. De Perrot T, et al

   . MRI with DWI for the detection of posttreatment head and neck squamous cell carcinoma: why morphologic MRI criteria matter. AJNR Am J Neuroradiol 2018;39:748–75 doi:10.3174/ajnr.A5548 pmid:29449279

   Abstract/FREE Full Text
10. 10.↵
    1. Becker M,
    2. Varoquaux AD,
    3. Combescure C, et al

    . Local recurrence of squamous cell carcinoma of the head and neck after radio(chemo)therapy: diagnostic performance of FDG-PET/MRI with diffusion-weighted sequences. Eur Radiol 2018;28:651–63 doi:10.1007/s00330-017-4999-1 pmid:28812148

    CrossRefPubMed
11. 11.↵
    1. Vaid S,
    2. Chandorkar A,
    3. Atre A, et al

    . Differentiating recurrent tumours from post-treatment changes in head and neck cancers: does diffusion-weighted MRI solve the eternal dilemma? Clin Radiol 2017;72:74–83 doi:10.1016/j.crad.2016.09.019 pmid:27789026

    CrossRefPubMed
12. 12.↵
    1. Wang C,
    2. Liu L,
    3. Lai S, et al

    . Diagnostic value of diffusion-weighted magnetic resonance imaging for local and skull base recurrence of nasopharyngeal carcinoma after radiotherapy. Medicine (Baltimore) 2018;97:e11929 doi:10.1097/MD.0000000000011929 pmid:30142809

    CrossRefPubMed
13. 13.↵
    1. Jajodia A,
    2. Aggarwal D,
    3. Chaturvedi AK, et al

    . Value of diffusion MR imaging in differentiation of recurrent head and neck malignancies from post treatment changes. Oral Oncol 2019;96:89–96 doi:10.1016/j.oraloncology.2019.06.037 pmid:31422219

    CrossRefPubMed
14. 14.↵
    1. Huang W,
    2. Liu J,
    3. Zhang B, et al

    . Potential value of non-echo-planar diffusion-weighted imaging of the nasopharynx: a primary study for differential diagnosis between recurrent nasopharyngeal carcinoma and post-chemoradiation fibrosis. Acta Radiol 2019;60:1265–72 doi:10.1177/0284185118822635 pmid:30661363

    CrossRefPubMed
15. 15.↵
    1. Page MJ,
    2. McKenzie JE,
    3. Bossuyt PM, et al

    . The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 2021;372:n71 doi:10.1136/bmj.n71 pmid:33782057

    FREE Full Text
16. 16.↵
    1. Stang A

    . Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol 2010;25:603–05 doi:10.1007/s10654-010-9491-z pmid:20652370

    CrossRefPubMedWeb of Science
17. 17.↵
    1. Deeks JJ,
    2. Dinnes J,
    3. D’Amico R, et al

    . Evaluating non-randomised intervention studies. Health Technol Assess 2003;7:1–173. iii–x doi:10.3310/hta7270 pmid:14499048

    CrossRefPubMed
18. 18.↵
    1. Surov A,
    2. Meyer HJ,
    3. Wienke A

    . Apparent diffusion coefficient for distinguishing between malignant and benign lesions in the head and neck region: a systematic review and meta-analysis. Front Oncol 2019;9:1362 doi:10.3389/fonc.2019.01362 pmid:31970081

    CrossRefPubMed
19. 19.↵
    1. Srinivasan A,
    2. Dvorak R,
    3. Perni K, et al

    . Differentiation of benign and malignant pathology in the head and neck using 3T apparent diffusion coefficient values: early experience. AJNR Am J Neuroradiol 2008;29:40–44 doi:10.3174/ajnr.A0743 pmid:17921228

    CrossRefPubMed
20. 20.↵
    1. Vandecaveye V,
    2. De Keyzer F,
    3. Vander Poorten V, et al

    . Head and neck squamous cell carcinoma: value of diffusion-weighted MR imaging for nodal staging. Radiology 2009;251:134–46 doi:10.1148/radiol.2511080128 pmid:19251938

    CrossRefPubMed
21. 21.↵
    1. Abdel Razek AA,
    2. Soliman NY,
    3. Elkhamary S, et al

    . Role of diffusion-weighted MR imaging in cervical lymphadenopathy. Eur Radiol 2006;16:1468–77 doi:10.1007/s00330-005-0133-x pmid:16557366

    CrossRefPubMed
22. 22.↵
    1. Lee MC,
    2. Tsai HY,
    3. Chuang KS, et al

    . Prediction of nodal metastasis in head and neck cancer using a 3T MRI ADC map. AJNR Am J Neuroradiol 2013;34:864– 69 doi:10.3174/ajnr.A3281 pmid:22997167

    Abstract/FREE Full Text
23. 23.↵
    1. Hatakenaka M,
    2. Nakamura K,
    3. Yabuuchi H, et al

    . Apparent diffusion coefficient is a prognostic factor of head and neck squamous cell carcinoma treated with radiotherapy. Jpn J Radiol 2014;32:80–89 doi:10.1007/s11604-013-0272-y pmid:24408077

    CrossRefPubMed
24. 24.↵
    1. Kim S,
    2. Loevner L,
    3. Quon H, et al

    . Diffusion-weighted magnetic resonance imaging for predicting and detecting early response to chemoradiation therapy of squamous cell carcinomas of the head and neck. Clin Cancer Res 2009;15:986–94 doi:10.1158/1078-0432.CCR-08-1287 pmid:19188170

    Abstract/FREE Full Text
25. 25.↵
    1. Srinivasan A,
    2. Chenevert TL,
    3. Dwamena BA, et al

    . Utility of pretreatment mean apparent diffusion coefficient and apparent diffusion coefficient histograms in prediction of outcome to chemoradiation in head and neck squamous cell carcinoma. J Comput Assist Tomogr 2012;36:131–37 doi:10.1097/RCT.0b013e3182405435 pmid:22261783

    CrossRefPubMed
26. 26.↵
    1. Sullivan BP,
    2. Parks KA,
    3. Dean NR, et al

    . Utility of CT surveillance for primary site recurrence of squamous cell carcinoma of the head and neck. Head Neck 2011;33:1547–50 doi:10.1002/hed.21636 pmid:21990217

    CrossRefPubMed
27. 27.↵
    1. Isles MG,
    2. McConkey C,
    3. Mehanna HM

    . A systematic review and meta-analysis of the role of positron emission tomography in the follow up of head and neck squamous cell carcinoma following radiotherapy or chemoradiotherapy. Clin Otolaryngol 2008;33:210–22 doi:10.1111/j.1749-4486.2008.01688.x pmid:18559026

    CrossRefPubMedWeb of Science
28. 28.↵
    1. Krieger DA,
    2. Hudgins PA,
    3. Nayak GK, et al

    . Initial performance of NI-RADS to predict residual or recurrent head and neck squamous cell carcinoma. AJNR Am J Neuroradiol 2017;38:1193–99 doi:10.3174/ajnr.A5157 pmid:28364010

    Abstract/FREE Full Text
29. 29.↵
    1. Strauss SB,
    2. Aiken AH,
    3. Lantos JE, et al

    . Best practices: application of NI-RADS for posttreatment surveillance imaging of head and neck cancer. AJR Am J Roentgenol 2021;216:1438–51 doi:10.2214/AJR.20.23841 pmid:32876470

    CrossRefPubMed
30. 30.↵
    1. Ashour MM,
    2. Darwish EA,
    3. Fahiem RM, et al

    . MRI posttreatment surveillance for head and neck squamous cell carcinoma: proposed MR NI-RADS criteria. AJNR Am J Neuroradiol 2021;42:1123–29 doi:10.3174/ajnr.A7058 pmid:33707288

    Abstract/FREE Full Text
31. 31.↵
    1. She D,
    2. Lin S,
    3. Guo W, et al

    . Grading of pediatric intracranial tumors: are intravoxel incoherent motion and diffusional kurtosis imaging superior to conventional DWI? AJNR Am J Neuroradiol 2021;42:2046–53 doi:10.3174/ajnr.A7270 pmid:34556474

    Abstract/FREE Full Text
32. 32.↵
    1. Wu J,
    2. Liang F,
    3. Wei R, et al

    . A multiparametric MR-based RadioFusionOmics Model with robust capabilities of differentiating glioblastoma multiforme from solitary brain metastasis. Cancers (Basel) 2021;13:5793 doi:10.3390/cancers13225793 pmid:34830943

    CrossRefPubMed
33. 33.↵
    1. Zhou Y,
    2. Gu HL,
    3. Zhang XL, et al

    . Multiparametric magnetic resonance imaging-derived radiomics for the prediction of disease-free survival in early-stage squamous cervical cancer. Eur Radiol 2021 Oct 12 [Epub ahead of print] doi:10.1007/s00330-021-08326-6 pmid:34642807

    CrossRefPubMed
34. 34.↵
    1. Thust SC,
    2. Maynard JA,
    3. Benenati M, et al

    . Regional and volumetric parameters for diffusion-weighted WHO Grade II and III glioma genotyping: a method comparison. AJNR Am J Neuroradiol 2021;42:441–47 doi:10.3174/ajnr.A6965 pmid:33414227

    Abstract/FREE Full Text